公开(公告)号：EP1979332A1

公开(公告)日：2008-10-15

申请号：EP07700377.0

申请日：2007-01-15

申请人： AstraZeneca AB

发明人： COWEN, Scott ,  DEEGAN, Tracy ,  GREWAL, Gurmit ,  OZA, Vibha ,  SAEH, Jamal, Carlos ,  SU, Qibin

IPC分类号： C07D249/08 ,  C07D401/06 ,  A61K31/4196 ,  A61P35/00

CPC分类号： C07D249/08 ,  C07D401/06

摘要： The invention relates to chemical compounds of formula (I) and (II) or pharmaceutically acceptable salts thereof, which possess Edg-1 antagonistic activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.

摘要翻译： 本发明涉及式（I）和（II）的化学化合物或其药学上可接受的盐，其具有Edg-1拮抗活性并因此可用于其抗癌活性并因此用于治疗人体或动物体的方法。 本发明还涉及制造所述化合物的方法，含有它们的药物组合物，以及它们在制备用于在温血动物例如人中产生抗癌作用的药物中的用途。

公开(公告)号：EP2346859A1

公开(公告)日：2011-07-27

申请号：EP09736268.5

申请日：2009-09-29

申请人： AstraZeneca AB

发明人： CHUAQUI, Claudio, Edmundo ,  HUANG, Shan ,  IOANNIDIS, Stephanos ,  SHI, Jie ,  SU, Mei ,  SU, Qibin

IPC分类号： C07D403/14 ,  C07D471/04 ,  C07D487/04 ,  C07D495/04 ,  C07D513/04 ,  A61K31/519 ,  A61P35/00

CPC分类号： C07D495/04 ,  C07D403/14 ,  C07D471/04 ,  C07D487/04 ,  C07D513/04

摘要： The present invention relates to compounds of Formula (I) and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds provide a treatment for myeloproliferative disorders and cancer.

公开(公告)号：EP4219470A1

公开(公告)日：2023-08-02

申请号：EP22209765.1

申请日：2018-01-16

申请人： Astrazeneca AB

发明人： NILSSON, Karl Magnus ,  ÅSTRAND, Annika Birgitta Margareta ,  BERGGREN, Anna Ingrid Kristina ,  JOHANSSON, Johan R ,  LEPISTÖ, Matti Juhani ,  KAWATKAR, Sameer Pralhad ,  SU, Qibin ,  KETTLE, Jason Grant

IPC分类号： C07D403/04 ,  C07D403/14 ,  A61K31/506 ,  A61P17/14 ,  A61P37/00

摘要： Disclosed herein are compounds of Formula (I),

and pharmaceutically acceptable salts thereof, wherein Ri-Rs have any of the meanings defined herein. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I) and methods of using the same.

公开(公告)号：EP2310010A2

公开(公告)日：2011-04-20

申请号：EP09772849.7

申请日：2009-07-02

申请人： AstraZeneca AB

发明人： DAKIN, Leslie ,  DOWLING, James, Edward ,  LAMB, Michelle ,  READ, Jon ,  SU, Qibin ,  ZHENG, Xiaolan

IPC分类号： A61K31/426 ,  A61K31/427 ,  A61P35/00 ,  C07D277/34

CPC分类号： C07D417/10 ,  A61K31/426 ,  A61K31/427 ,  C07D277/34 ,  C07D417/06 ,  C07D417/12 ,  C07D417/14

摘要： The invention relates to chemical compounds of formula (I), and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of PIM-1 and/or PIM-2, and/or PIM-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of PIM kinase related conditions and diseases, preferably cancer.

公开(公告)号：EP2094670A1

公开(公告)日：2009-09-02

申请号：EP07824500.8

申请日：2007-11-08

申请人： AstraZeneca AB

发明人： GREWAL, Gurmit ,  HENNESSY, Edward ,  KAMHI, Victor ,  LI, Danyang ,  LYNE, Paul ,  OZA, Vibha ,  SAEH, Jamal Carlos ,  SU, Qibin ,  YANG, Bin

IPC分类号： C07D235/14 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D407/12 ,  C07D409/12 ,  C07D413/06 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D473/40 ,  C07D487/04 ,  C07D491/056

CPC分类号： C07D235/14 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D407/12 ,  C07D409/12 ,  C07D413/06 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D473/40 ,  C07D487/04 ,  C07D491/056

摘要： The invention relates to chemical compounds of formula (I), (Ia) and (Ib) or pharmaceutically acceptable salts thereof, which possess Edg-1 antagonistic activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an anti-cancer effect in a warm-blooded animal, such as man.

公开(公告)号：EP3571192A1

公开(公告)日：2019-11-27

申请号：EP18701296.8

申请日：2018-01-16

申请人： Astrazeneca AB

发明人： NILSSON, Karl, Magnus ,  ÅSTRAND, Annika, Birgitta, Margareta ,  BERGGREN, Anna, Ingrid, Kristina ,  JOHANSSON, Johan, R. ,  LEPISTÖ, Matti, Juhani ,  KAWATKAR, Sameer, Pralhad ,  SU, Qibin ,  KETTLE, Jason, Grant

IPC分类号： C07D403/04 ,  C07D403/14 ,  A61K31/506 ,  A61P17/14 ,  A61P37/00

公开(公告)号：EP2188255A1

公开(公告)日：2010-05-26

申请号：EP08788726.1

申请日：2008-08-29

申请人： AstraZeneca AB

发明人： DAKIN, Leslie ,  FAUBER, Benjamin ,  HIRD, Alexander ,  JANETKA, James ,  RUSSELL, Daniel, John ,  SU, Qibin ,  YANG, Bin ,  ZHENG, XiaoLan

IPC分类号： C07D213/30 ,  C07D213/40 ,  C07D213/73 ,  C07D233/61 ,  C07D401/12 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D473/00 ,  C07D513/04 ,  A61K31/40 ,  A61K31/41 ,  A61K31/435 ,  A61K31/4427 ,  A61P35/00

CPC分类号： C07D401/12 ,  C07D213/30 ,  C07D213/40 ,  C07D213/73 ,  C07D233/61 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D473/00 ,  C07D513/04

摘要： The present disclosure relates to heterocyclic amide compounds, which are useful for inhibiting the Hedgehog pathway, and their use in treating a disease or medical condition mediated alone or in part by Hedgehog pathway inhibition. Also disclosed are methods for manufacture of these compounds, pharmaceutical compositions including these compounds, and use of these compounds in the manufacture of medicaments for treating such diseases and medical conditions in a subject. Formula (IA) with the provisio that either R2or R3 is (Z).

公开(公告)号：EP2013186A1

公开(公告)日：2009-01-14

申请号：EP07732487.9

申请日：2007-04-20

申请人： AstraZeneca AB

发明人： GREWAL, Gurmit ,  OZA, Vibha ,  SAEH, Jamal, Carlos ,  SU, Qibin

IPC分类号： C07D233/54 ,  A61K31/41 ,  A61P35/00

CPC分类号： C07D233/64

摘要： The invention relates to chemical compounds of formula (I): or pharmaceutically acceptable salts thereof, which possess Edg-1 antagonistic activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.

公开(公告)号：EP2013184A1

公开(公告)日：2009-01-14

申请号：EP07732469.7

申请日：2007-04-20

申请人： AstraZeneca AB

发明人： GREWAL, Gurmit ,  HENNESSY, Edward ,  KAMHI, Victor ,  LI, Danyang ,  OZA, Vibha ,  SAEH, Jamal, Carlos ,  SU, Qibin

IPC分类号： C07D231/12 ,  C07D231/20 ,  C07D231/38 ,  C07D261/08 ,  C07D261/10 ,  C07D261/12 ,  C07D275/02 ,  A61P7/02 ,  A61P9/10 ,  A61P19/02 ,  A61P31/00 ,  A61P35/00 ,  A61K31/415 ,  A61K31/42 ,  A61K31/425

CPC分类号： C07D231/12 ,  C07D231/20 ,  C07D231/38 ,  C07D261/08 ,  C07D261/10 ,  C07D261/12 ,  C07D275/02 ,  C07D275/03

摘要： The present invention relates to compounds of formula (I) that mediate Edg, including Edg-1, 1 processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases that have a significant vascularization or inflammatory component such as in tumor-related diseases. The present invention also relates to compounds that inhibit a5b1, and also that exhibit appropriate selectivity profile(s) against other integrins.